Can Fite Biopharma Ltd (CANF) has a current Price-to-Book (P/B) ratio of 208.73. Compared to its 3-year average P/B ratio of 329.84, the current P/B ratio is approximately -36.72% higher. Relative to its 5-year average P/B ratio of 196.60, the current P/B ratio is about 6.17% higher. Can Fite Biopharma Ltd (CANF) has a Forward Free Cash Flow (FCF) yield of approximately -33.91%. Compared to its 3-year average FCF yield of -45.53%, the current FCF yield is approximately -25.51% lower. Relative to its 5-year average FCF yield of -35.61%, the current FCF yield is about -4.76% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CANF competitors is 46.36, providing a benchmark for relative valuation. Can Fite Biopharma Ltd Corp (CANF.A) exhibits a P/S ratio of 243.93, which is 426.11% above the industry average. Given its robust revenue growth of -21.32%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CANF increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CANF in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CANF currently overvalued or undervalued?

What is Can Fite Biopharma Ltd (CANF) fair value?

CANF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Can Fite Biopharma Ltd (CANF) is between to according to relative valuation method.

How does CANF's valuation metrics compare to the industry average?

The average P/S ratio for CANF's competitors is 46.36, providing a benchmark for relative valuation. Can Fite Biopharma Ltd Corp (CANF) exhibits a P/S ratio of 243.93, which is 426.11% above the industry average. Given its robust revenue growth of -21.32%, this premium appears unsustainable.

What is the current P/B ratio for Can Fite Biopharma Ltd (CANF) as of Mar 03 2026?

As of Mar 03 2026, Can Fite Biopharma Ltd (CANF) has a P/B ratio of 208.73. This indicates that the market values CANF at 208.73 times its book value.

What is the current FCF Yield for Can Fite Biopharma Ltd (CANF) as of Mar 03 2026?

As of Mar 03 2026, Can Fite Biopharma Ltd (CANF) has a FCF Yield of -33.91%. This means that for every dollar of Can Fite Biopharma Ltd's market capitalization, the company generates -33.91 cents in free cash flow.

What is the current Forward P/E ratio for Can Fite Biopharma Ltd (CANF) as of Mar 03 2026?

As of Mar 03 2026, Can Fite Biopharma Ltd (CANF) has a Forward P/E ratio of -0.83. This means the market is willing to pay $-0.83 for every dollar of Can Fite Biopharma Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Can Fite Biopharma Ltd (CANF) as of Mar 03 2026?

As of Mar 03 2026, Can Fite Biopharma Ltd (CANF) has a Forward P/S ratio of 243.93. This means the market is valuing CANF at $243.93 for every dollar of expected revenue over the next 12 months.

CANF Valuation